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Abstract
Smoking Cessation Treatment (SCT) is a policy that has to be promoted for health econom-
ics, and expectations for the success of treatments with varenicline (VAR) are large. How-
ever, the Food and Drug Administration (FDA) have issued a warning on VAR-induced
depression and suicide. In the present study, utilizing the FDA Adverse Event Reporting
System (FAERS), we searched for antidepressants (ADs) used during SCT that cause
fewer suicide-related events (SRE) (Study 1). We also investigated whether VAR concomi-
tantly administered with ADs increases the risk of SRE (Study 2). In addition, we investi-
gated whether the use of VAR alone is a latent risk factor of SRE. The backgrounds of
cases with and without SRE were matched using the Propensity Score. In Study 1, the
highest integrated Reporting Odds Ratio (iROR) was noted in concomitantly administered
mirtazapine (iROR 6.98; 95% Confidence Interval (CI) 1.57–30.99), while the lowest ratio
was noted in concomitantly administered amitriptyline (iROR 0.59; iROR95%CI 0.23–
1.50). Study 2 clarified that SCT increases the risk of SRE in AD-treated cases (iROR 8.02;
iROR95%CI 5.47–11.76; not significance). Of ADs concomitantly used during SCT with
VAR, amitriptyline and mirtazapine showed the lowest and highest risks, respectively
(Study 1). It was clarified that concomitant use of VAR in the treatment of depression with
ADs increased the risk of SRE (Study 2). The results of Studies 1 and 2 suggested that the
use of VAR alone is a latent risk factor inducing suicide.
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Introduction
Cigarette smoking is a risk factor for various diseases, such as cancers including lung cancer,
chronic obstructive pulmonary disease (COPD), hypertension, ischemic heart disease, and
cerebrovascular disorders. According to theWHO, more than 6 million people die annually
due to cigarette smoking [1]. Medical and social economic losses due to cigarette smoking are
approximately 1.8 and 2.4 trillion yen (approximately 15 and 20 billion dollars), respectively,
in Japan [2], and approximately 170 and 156 billion dollars, respectively, in the US [3,4].
Therefore, the cost-effectiveness of smoking cessation treatment (SCT) for the prevention of
secondary diseases is high [5], and it is recommended as part of health care cost controls. Phar-
macological treatments are used as SCT, of which there are 2 types: ‘nicotine replacement ther-
apy using nicotine preparations’ and ‘the use of the partial agonist of the nicotinic
acetylcholine receptor, varenicline (VAR)’. A previous study reported that VAR is less likely to
cause nicotine withdrawal symptoms and has a higher success rate than nicotine preparations
[6]; therefore, it is regarded as an important drug for the promotion of non-smoking policies.
However, VAR has been implicated in the aggravation of mental diseases, such as depres-
sion, and suicide, and, as a consequence, the Food and Drug Administration (FDA) issued a
warning in 2009 [7]. In Japan, the following description was added to the warning column of
the package insert: It may aggravate underlyingmental diseases. In the retrieval system in Japa-
nese, CzeekV (2015/04/13 access, version 2.1.1), of the FDA voluntary adverse event report
database, the Adverse Event Reporting System (FAERS), VAR is ranked in first place in the
overall ranking of signals of suicidal ideation and behavior. On the other hand, a meta-analysis
of randomized controlled studies showed that VAR was not associated with depression or sui-
cide [8]. Therefore, while VAR is unlikely to cause depression and suicide, smoking cessation
itself has been suggested to induce depression and suicide [9], and cigarette smokers are at a
high risk of depression [10].
SSRI and SNRI, which cause few adverse reactions, are currently used as first-line drugs to
treat depression [11]; however, an increase in the risk of suicide by the administration of anti-
depressants (ADs) was confirmed in a placebo controlled trial, and the FDA issued a warning
for all SSRIs in 2003. Moreover, several studies reported AD-induced increases in suicide-
related events (SRE) [12–14]. On the other hand, after a warning concerning ADs and suicide
was issued in the US and Europe, the prescription rate of ADs decreased in the Netherlands
with a simultaneous increase in the suicide rate [15], whereas an inverse correlation was noted
between the number of prescriptions for ADs and suicidemortality [16], showing different
study results due to differences in the study method.
Smoking cessation is economically important and a policy that needs to be promoted, as
described above; however, the development of depression and SRE during SCT represents a
major obstacle to smoking cessation.
Thus, we herein attempted to identify ADs with the lowest risk of SRE among the ADs con-
comitantly used in SCT with VAR from the viewpoint of the safe use of drugs by comparing the
risk of SRE betweenVAR-treated cases with (ADs+/VAR+) and without (ADs-/VAR+) con-
comitant ADs treatment (Study 1). The risks associated with the administration of VAR were
investigated, with consideration of the information provided by the regulatory agency that
‘VAR aggravates mental disease’. AD-treated cases were divided into those with (VAR+/ADs+)
and without (VAR-/ADs+) concomitantly administered VAR and were then compared in order
to examine whether VAR increases the risk of SRE (Study 2). The risk of SRE was standardized
by regarding the risk as identical betweenADs+/VAR+ in Study 1 and VAR+/ADs+ in Study 2,
and the risk was compared betweenADs-/VAR+ and VAR-/ADs+ to investigate the risk of SRE
in VAR-treated cases without ADs, i.e., the latent risk of the use of VAR.
Assessment of Latent Risk by the Use of Varenicline
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Methods
Study 1: Concomitant AD-associated risk of SRE in VAR-treated (SCT)
cases
Definition of SRE. In the ICHMedical Dictionary for RegulatoryActivities/Japanese ver-
sion (MedDRA/J), the SMQ classification of SRE includes the following terms at the Preferred
Term (PT) level: Completed suicide (MedDRA code 10010144), suicidal ideation (10042458),
suicide attempt (10042464), suicidal behavior (10065604), self-injurious ideation (10051154),
self-injurious behavior (10063495), depression suicidal (10012397), intentional self-injury
(10022524), poisoning deliberate (10036000), and intentional overdose (10022523), and these
were collectively defined as SRE.
Data extraction and adjustment. Since FAERS adopts a free-description style to enable
reporting with ease, incorrect inputs and overlapping data are included. CzeekV is a unique
system that organizes these data and enables searches in Japanese [17]. In the present study, all
VAR-treated cases were collected from CzeekV (version 2.1.1), cases treated with 2 or more
ADs were excluded, and the remaining cases were adopted as an analysis set for the case-con-
trol study. The data of this system is replaced FAERS database in Japanese. Therefore, the data-
set in this study do not include any of identifying information. In order to remove selection
biases as much as possible, after stratifying by gender, cases were matched based on the Pro-
pensity Score (PS) using the Statistical Package for Social Science (SPSS, version 22). In the PS
estimation, 3 case background factors: age, body weight, and number of concomitantly admin-
istered drugs, were regarded as covariates, and the presence or absence of SRE was regarded as
the outcome. It was not possible to apply stratification by disease severity because it was not
included in case reports in FAERS. Although age was reported in many cases, the number was
insufficient to analyze cases stratified by gender. Thus, only stratification by gender, a factor
influencing the drug effect, was applied. A multiple logistic regression analysis employing the
stepwise method was used in the PS estimation, and the PS distance (caliper value) was defined
as ‘0.25 x the standard deviation of the logit transformation-applied PS estimate’. Using the PS
estimate and caliper value, the SRE+ and SRE- (control) groups were matched. The standard-
ized difference (SDD) was calculated in order to evaluate the balance of covariates of the
matched data [18]. An SDD value of less than 0.1 was regarded as balanced [19]. A flow chart
of the process used for reporting odds ratio (ROR) calculations is shown in Fig 1.
Calculationof the ROR and corresponding 95% confidence interval (ROR95%CI). In
order to investigate the risk of SRE in VAR-treated cases with concomitant ADs (ADs+/VAR
+) using matched data, the ROR and ROR95%CI were calculated in each gender with the con-
comitant use of ADs as a factor and in the presence or absence of SRE as the outcome. In addi-
tion, the uniformity of ROR of the matched data between genders was evaluated using the
Breslow-Day Test, and when ROR was uniform, the integrated ROR (iROR) and correspond-
ing 95% CI (iROR95%CI) of ADs were calculated using the Mantel-Haenszel Test. We cor-
rected the significance level by employing the Bonferroni method in consideration of the alpha
error made by multiple comparisons [20].
Study 2: Concomitant VAR (SCT)-associated risk of SRE in AD-treated
cases
In order to investigate the risk of SRE in AD-treated cases with concomitantly administered
VAR (VAR+/ADs+), AD-treated cases were collected, and those using only one AD were
extracted. PS was estimated after stratification of this analysis set by gender, as described in
Study 1. Cases were divided into those with and without SRE, and the 2 groups were matched.
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In addition, in order to investigate the influence of concomitantly administered VAR (SCT) on
SRE using matched data, ROR and ROR 95% CI were calculatedwith the concomitant use of
VAR as a factor and in the presence or absence of SRE as the outcome. The uniformity of
matched data between genders was evaluated using the Breslow-Day Test, and when ROR was
uniform, iROR and iROR95%CI of the AD were calculated using the Mantel-Haenszel Test.
Results
Study 1: Concomitant AD-associated risk of SRE in VAR-treated (SCT)
cases
Changes in the number of VAR-treated cases with the flowchart in Fig 1 are shown in S1
Table. The balance of the covariates before and after matching is shown in S2 Table. The SDD
values of all covariates after matching were less than 0.1, which was close to randomization.
Using matched data, ROR and ROR 95% CI were calculated with the presence or absence of
concomitantly administered ADs in VAR-treated cases as a factor and in the presence or
Fig 1. Flowchart for ROR calculations. * Reporting Odds Ratio. ** integrated Reporting Odds Ratio.
doi:10.1371/journal.pone.0163583.g001
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absence of SRE as an outcome. The results obtained are summarized in Table 1 (see the mini-
mal dataset in S3 Table).
In male cases (Table 1-male), concomitantly administered ADs significantly increased the
risk of SRE (ROR 2.02, ROR95%CI 1.28–3.19). Nine types of ADs were extracted, as shown in
Table 1-male. None of the antidepressants tested significantly increased the risk of SRE after
the correction of the significance level by the Bonferroni method.
Concomitantly administered ADs also significantly increased the risk of SRE in female cases
(ROR 2.09, ROR95%CI 1.58–2.76) (Table 1-female). Sixteen types of ADs were extracted, as
shown in Table 1-female. None of the antidepressants tested significantly increased the risk of
SRE after the correction of the significance level by the Bonferronimethod.
The results of the ROR uniformity test (Breslow-Day Test) and iROR calculation (Mantel-
Haenszel Test) are shown in Table 2. As shown by values marked with a in Table 2, the ROR of
citalopram was not uniform between the genders. In the other ADs, ROR was uniform and it
was possible to calculate iROR. As shown in Table 2, concomitantly administered ADs signifi-
cantly increased the risk of SRE (iROR 2.07, iROR95%CI 1.63–2.63), while only duloxetine
(ROR 2.94, ROR95%CI 1.41–6.10) significantly increased the risk of SRE. iROR was less than
1.00 in amitriptyline-treated cases only, but was not significant. Since there was no reported
male case of concomitantly administered nortriptyline, amoxapine, clomipramine, trimipra-
mine, lofepramine, or imipramine, it was impossible to investigate uniformity.
Study 2: Concomitant VAR (SCT)-associated risk of SRE in AD-treated
cases
Changes in the number of AD-treated cases with the flowchart in Fig 1 are shown in S1 Table.
The 8 types of ADs, the ROR of which were recognized as uniform in Table 2, were analyzed in
Study 2. Cases treated with these 8 drugs were stratified by gender and 1-to-1 matched. The
results obtained are shown in S2 Table. Using matched data, ROR and ROR 95% CI were calcu-
lated in the presence or absence of concomitantly administered VAR in AD-treated cases as a
factor and in the presence or absence of SRE as an outcome. The results obtained are summa-
rized in Table 3.
In male cases (Table 3-male), when the type of AD was not specified, concomitantly admin-
istered VAR significantly increased the risk of SRE (ROR 6.37, ROR95%CI 3.14–12.90).
Regarding ADs, concomitantly administered VAR did not significantly increase the risk of SRE
in cases treated with any of the antidepressants tested after the correction of the significance
level (see the minimal dataset in S4 Table).
Similarly, in female cases (Table 3-female), when the type of AD was not specified, concom-
itantly administered VAR significantly increased the risk of SRE (ROR 8.23, ROR95%CI 5.53–
13.76). Regarding ADs, after the correction of the significance level, concomitantly adminis-
tered VAR significantly increased the risk of SRE in cases treated with sertraline (ROR 25.21,
ROR95%CI 3.40–187.13), fluoxetine (ROR 8.62, ROR95%CI 3.02–24.60), and venlafaxine
(ROR 7.35, ROR95%CI 2.56–21.10) (see the minimal dataset in S4 Table).
The results of the ROR uniformity test (Breslow-Day Test) and iROR calculation (Mantel-
Haenszel Test) for each of the 8 ADs are shown in Table 4. Based on Table 4, when the type of
AD was not specified, concomitantly administered VAR significantly increased the risk of SRE
(iROR 8.02, iROR95%CI 5.47–11.76). Regarding ADs, concomitantly administeredVAR signifi-
cantly increased the SRE risk in cases treated with sertraline (iROR 10.97, iROR95%CI 3.21–
37.51), venlafaxine (iROR 6.88, iROR95%CI 2.67–17.74), fluoxetine (iROR 6.34, iROR95%CI
2.80–14.35), and bupropion (iROR 4.02, iROR95%CI 1.60–10.12). Calculations were not possi-
ble for amitriptyline, mirtazapine, or duloxetine because complete data were not available.
Assessment of Latent Risk by the Use of Varenicline
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Discussion
Study 1: Concomitant AD-associated risk of SRE in VAR-treated (SCT)
cases
In male and female cases, none of the antidepressants tested significantly increased the risk of
SRE (Table 1). However, when the genders were combined, concomitant duloxetine signifi-
cantly increased the risk of SRE over that in the control group (Table 2). Furthermore, although
Table 1. Influence of concomitantly administered ADs on the risk of SRE in VAR-treated cases.
Male
VAR-treated cases
ADs+/VAR+ ADs-/VAR+
SRE+ SRE- SRE+ SRE- ROR ROR 95%CI p-value
All AD-treated cases 58 30 601 629 2.02 1.28–3.19 0.002*
By drug
Mirtazapine 7 1 601 629 7.33 0.90–59.73 0.063
Citalopram 12 2 601 629 6.28 1.40–28.18 0.016
Bupropion 9 4 601 629 2.35 0.72–7.69 0.157
Duloxetine 6 3 601 629 2.09 0.52–8.41 0.299
Fluoxetine 5 3 601 629 1.74 0.42–7.33 0.45
Venlafaxine 5 3 601 629 1.74 0.42–7.33 0.45
Sertraline 9 6 601 629 1.57 0.56–4.44 0.395
Amitriptyline 2 2 601 629 1.05 0.15–7.45 0.961
Paroxetine 3 3 601 629 1.05 0.21–5.21 0.952
Female
VAR-treated cases
ADs+/VAR+ ADs-/VAR+
SRE+ SRE- SRE+ SRE- ROR ROR 95%CI p-value
All AD-treated cases 163 86 746 823 2.09 1.58–2.76 < 0.001*
By drug
Mirtazapine 6 1 746 823 6.62 0.80–55.11 0.08
Sertraline 19 6 746 823 3.49 1.39–8.79 0.008
Duloxetine 21 7 746 823 3.31 1.40–7.83 0.006
Bupropion 15 6 746 823 2.76 1.06–7.15 0.037
Fluoxetine 27 14 746 823 2.13 1.11–4.09 0.023
Venlafaxine 25 13 746 823 2.12 1.08–4.18 0.03
Trazodone 6 4 746 823 1.65 0.47–5.89 0.439
Citalopram 12 13 746 823 1.02 0.46–2.25 0.961
Amitriptyline 5 11 746 823 0.5 0.17–1.45 0.201
Paroxetine 21 0 746 823 Inf 5.71—Inf not calculated
Nortriptyline 3 0 746 823 Inf 0.45—Inf not calculated
Amoxapine 1 0 746 823 Inf 0.03 -Inf not calculated
Clomipramine 1 0 746 823 Inf 0.03 -Inf not calculated
Trimipramine 1 0 746 823 Inf 0.03 -Inf not calculated
Lofepramine 1 0 746 823 Inf 0.03 -Inf not calculated
Imipramine 0 1 746 823 0 0.00—Inf not calculated
Inf, infinite.
* significantly different after Bonferroni’s correction for multiple comparisons.
doi:10.1371/journal.pone.0163583.t001
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a significant difference was not detected, iROR, i.e., the risk of SRE, varied among the antide-
pressants concomitantly administered to VAR-treated cases. For example, the risk of amitrip-
tyline-induced SRE was the lowest among the antidepressants tested, but was not significant
(ROR = 0.59, ROR95%CI 0.23–1.50). In addition, iROR was less than 1.00 in amitriptyline-
treated cases only, suggesting that the concomitant use of amitriptyline reduces the risk of SRE
more that in the control group. The number of citalopram-treated cases was high in both gen-
ders, and ROR was not uniform in the Breslow-Day Test in citalopram-treated cases only.
Thus, the risk of SRE differed between the genders (Table 1). However, the absence of a gender
difference has been reported in the drug effects of citalopram [21], suggesting that this result
was incidental.
Since Carol et al. [22] reported that the hazard ratio for AD-associated completed suicide
was significantly low in amitriptyline-treated cases only, amitriptyline may have SRE risk-
reducing effects. Amitriptyline is more frequently used at specializedmedical institutions, and
the lower risk of SRE in amitriptyline-treated cases may have been due to the management of
depressive symptoms and adverse effects at these medical institutions.
Study 2: The risk of SRE associated with the concomitant administration
of VAR (SCT) in AD-treated cases
It was not possible to calculate iROR95%CI for amitriptyline, mirtazapine, or duloxetine. Con-
comitantly administered VAR may have increased the risk of SRE, regardless of the type of
AD, over that in the control group, showing that SCT with VAR is likely to increase the risk of
depression-associated suicide. Amitriptyline decreased the risk of SRE in Study 1, but not in
Study 2.
Potential of SCT as a latent factor of SRE
The iROR of integrated male and female data in Studies 1 and 2 is shown in Fig 2A. iROR was
high in Study 2, indicating that the concomitant VAR-associated risk in AD-treated cases
(Study 2) was higher than the concomitant AD-associated risk in VAR-treated cases (Study 1).
Table 2. Uniformity test of ROR (Breslow-Day Test) and calculation of integrated ROR (Mantel-Haenszel Test) in VAR-treated cases.
Breslow-Day Test Mantel-Haenszel Test
χ2-value Df p-value iROR iROR95%CI p-value
All AD-treated cases 0.015 1.00 0.904 2.07 1.63–2.63 < 0.001*
By drug
Mirtazapine 0.004 1.00 0.947 6.98 1.57–30.99 0.007
Duloxetine 0.304 1.00 0.581 2.94 1.41–6.10 0.004*
Bupropion 0.042 1.00 0.838 2.59 1.24–5.45 0.015
Sertraline 1.296 1.00 0.255 2.52 1.26–5.02 0.009
Fluoxetine 0.061 1.00 0.805 2.06 1.14–3.73 0.022
Venlafaxine 0.059 1.00 0.809 2.05 1.11–3.78 0.028
Trazodone 0.194 1.00 0.660 1.39 0.51–3.76 0.518
Amitriptyline 0.427 1.00 0.513 0.59 0.23–1.50 0.360
Citalopram 5.010 1.00 0.025a # # not calculated
df, degree of freedom.
a non-uniformity.
# Value could not be calculated due to the non-uniformity of ROR.
* significantly different after Bonferroni’s correction for multiple comparisons.
doi:10.1371/journal.pone.0163583.t002
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Table 3. Influence of concomitantly administered VAR on the risk of SRE in AD-treated cases.
Male
AD-treated cases
VAR+/ADs+ VAR-/ADs+
SRE+ SRE- SRE+ SRE- ROR ROR 95%CI p-value
All AD-treated cases 56 9 1574 1621 6.37 3.14–12.90 < 0.001*
Bupropion 8 1 178 185 8.31 1.03–67.16 0.047
Venlafaxine 5 1 282 286 5.07 0.59–43.68 0.14
Sertraline 8 2 372 378 4.06 0.86–19.27 0.078
Fluoxetine 10 3 236 243 3.43 0.93–12.62 0.064
Trazodone 1 1 19 19 1 0.01–82.52 1.000
Mirtazapine 8 0 49 57 Inf 1.86—Inf not calculated
Duloxetine 6 0 184 190 Inf 1.19—Inf not calculated
Amitriptyline 1 0 80 81 Inf 0.03—Inf not calculated
Female
AD-treated cases
VAR+/ADs+ VAR-/ADs+
SRE+ SRE- SRE+ SRE- ROR ROR 95%CI p-value
All AD-treated cases 174 21 2884 3037 8.23 5.53–13.76 < 0.001*
Sertraline 24 1 456 479 25.21 3.40–187.13 0.002*
Fluoxetine 32 4 364 392 8.62 3.02–24.60 < 0.001*
Venlafaxine 28 4 483 507 7.35 2.56–21.10 < 0.001*
Trazodone 6 1 52 57 6.58 0.77–56.47 0.086
Amitriptyline 5 1 86 90 5.23 0.60–45.71 0.135
Bupropion 15 5 216 226 3.14 1.12–8.79 0.029
Duloxetine 23 0 383 406 Inf 6.03—Inf not calculated
Mirtazapine 6 0 60 66 Inf 1.23—Inf not calculated
Inf, infinite.
* significantly different after Bonferroni’s correction for multiple comparisons.
doi:10.1371/journal.pone.0163583.t003
Table 4. Uniformity test of ROR (Breslow-Day Test) and calculation of integrated ROR (Mantel-Haenszel Test) in AD-treated cases.
Breslow-Day Test Mantel-Haenszel Test
χ2-value Df p-value iROR iROR95%CI p-value
All AD-treated cases 0.520 1.00 0.471 8.02 5.47–11.76 < 0.001*
Sertraline 2.397 1.00 0.122 10.97 3.21–37.51 < 0.001*
Venlafaxine 0.093 1.00 0.761 6.88 2.67–17.74 < 0.001*
Fluoxetine 1.210 1.00 0.271 6.34 2.80–14.35 < 0.001*
Bupropion 0.708 1.00 0.400 4.02 1.60–10.12 0.002*
Trazodone 1.204 1.00 0.273 3.71 0.67–20.61 0.172
Amitriptyline 0.189 1.00 0.664 6.29 # not calculated
Mirtazapine # # # # # not calculated
Duloxetine # # # # # not calculated
df, degree of freedom.
# Calculations were not possible because no case was reported.
* significantly different after Bonferroni’s correction for multiple comparisons.
doi:10.1371/journal.pone.0163583.t004
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However, this comparison was not possible because the background of the control group dif-
fered between Studies 1 and 2 (ADs-/VAR+ and VAR-/ADs+, respectively). Thus, assuming
that the case groups common to both studies, VAR+/ADs+ and ADs+/VAR+, were similar
populations, the iROR of these groups were regarded as 1.00 for the baseline in adjustments.
The results obtained are shown in Fig 2B. VAR-/ADs+ and ADs-/VAR+ were compared in Fig
2B. The bar graph of ADs-/VAR+ was higher than that of VAR-/ADs+, suggesting that SCT
with VAR is a latent factor increasing the risk of SRE more than that by ADs used to treated
depression.
SCT with VAR has been suggested to increase the risk of SRE. However, it currently remains
unclear whether VAR itself has a suicide-inducing effect or SCT induces suicide in smokers
already at risk of suicide. Factors inducing suicide include ‘issues with patients themselves,
such as SCT with VAR and mental disorders’ and ‘the social environment of patients, such as
stigma from a patient’s family and medical health professionals’ [23]. An accurate evaluation
of the suicide-inducing risk of the latter is difficult because cases cannot be collected from
those reported to FAERS. However, as shown in Fig 2B, the risk of SRE was higher in ADs-/
VAR+, in which stigma was not an inducer of SRE, than in VAR-/ADs+, and this did not over-
estimate the risk of SRE associated with the administration of VAR.
Limitations
Data from FAERS were analyzed, but only a small number of case reports included gender, the
3 covariates, and adverse events because FAERS adopts the free-description style, and there
were many missing data. For example, out of 57,440 VAR-treated cases that were regarded as
an analysis set in Study 1, all covariates were reported in 23,008 cases only, and, thus, approxi-
mately 60% were not included in the PS estimation. It is possible that an accurate ROR may
not have been calculated.
Since case reports in FAERS are cross-sectional, the order of timing of taking drugs and the
development of several diseases in a case is currently unclear. Therefore, cases that started
Fig 2. (A) Unadjusted iROR and (B) adjusted iROR of varenicline (VAR) and antidepressants (ADs) determined
by matching in each study.
doi:10.1371/journal.pone.0163583.g002
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smoking cessation during the treatment of depression may have been included among cases
that developed depression during SCT, thereby influencing the ROR estimation.
Since the number of covariates is ideally 1/10-1/7 of the number of cases in PS estimations,
the number of covariates was insufficient in the present study. When PS is estimated and
matched in analyses with a small number of covariates, it is possible that cases with close PS,
but a different balance of covariates were matched.
Conclusion
The treatment of depression with ADs during SCT with VAR is more likely to increase the risk
of SRE more than that with the treatment of depression with ADs (control group). SCT with
VAR has been suggested as a latent factor inducing depression and SRE, and the risk associated
with this treatment is stronger than that associated with the treatment of depression with ADs.
When depression develops during SCT, the risk of SRE increases, for which concomitant
amitriptyline may decrease the risk of suicide. In contrast, concomitant mirtazapine may
increase the risk of SRE because its iROR was the highest.
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